...Inbar Cohen; Iuliana Vaxman; Morie A. Gertz Background: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become part of standard of care (SOC) in newly diagnosed multiple myeloma. In this review, we provide a historical perspective on ASCT since its introduction...

... and suggests that VCB is a highly effective induction regimen that confers a post-HDT advantage. High-dose therapy Multiple myeloma Vincristine, doxorubicin and dexamethasone regimen Bortezomib is a boronic acid dipeptide small-molecule proteasome inhibitor. It promotes apoptosis, prevents DNA repair...

...Pier Luigi Zinzani Early studies on high-dose therapy followed by autologous bone marrow transplantation demonstrated the safety and efficacy of this approach in non-Hodgkin’s lymphoma (NHL). As the procedure became easier and safer with the introduction of peripheral blood progenitor cells instead...

... randomized studies high-dose therapy in metastatic breast cancer leads to an equivalent or better disease-free survival, but because of their low power, none of these studies achieved an improvement in overall survival. It is thus necessary to perform a meta-analysis of all these studies to acquire insight...

...Muzaffar H. Qazilbash; Marcel P. Devetten; Jame Abraham; Joseph P. Lynch; Charles L. Beall; Miklos Auber; Robin Weisenborn; Pam Bunner; Solveig G. Ericson We evaluated the results of high-dose therapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with relapsed...